Taysha Gene Therapies Profit Margin

The latest profit margin for TSHA is -1738.4% as of March 2026. That compares with -1201.08% in the prior-year period — down 44.7% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Taysha Gene Therapies's historical trend and sector peers before judging valuation or financial health.

Over the past year, TSHA's profit margin moved from -1201.08% to -1738.4% — a 44.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Taysha Gene Therapies's valuation or profitability profile.

Against Healthcare companies, TSHA currently prints -1738.4% for profit margin, while the sector average sits near 15.29%. That is roughly 11467.4% below the sector mean. Large gaps often invite a closer look at Taysha Gene Therapies's growth, margins, and balance sheet.

Profit Margin shows how effectively Taysha Gene Therapies converts resources into returns. At -1738.4%, TSHA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1201.08% in the prior-year period — down 44.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TSHA's profit margin (-1738.4%), review year-over-year change from -1201.08%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.